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ABSTRACT
Purpose: Ridaforolimus is an investigational, potent, selective mTOR inhibitor. 
This study was conducted to determine the recommended phase 2 dose (RP2D), 
maximum tolerated dose, safety, pharmacokinetics, and antitumor activity of oral 
ridaforolimus in children with advanced solid tumors.
Experimental Design: In this phase 1, multicenter, open-label study in children 
aged 6 to <18 years with advanced solid tumors, ridaforolimus was administered 
orally for 5 consecutive days/week in 28-day cycles until progression, unacceptable 
toxicity, or consent withdrawal. Dose started at 22 mg/m2 and increased to 28 mg/
m2 and 33 mg/m2, followed by expansion at the RP2D.
Results: Twenty patients were treated; 18 were evaluable for dose-limiting 
toxicities. One dose-limiting toxicity (grade 3 increased alanine aminotransferase) 
occurred in 1 patient at 33 mg/m2. Dose escalation concluded at 33 mg/m2; the 
maximum tolerated dose was not determined. The most common treatment-
related adverse events (frequency ≥40%) were manageable grade 1–2 stomatitis, 
thrombocytopenia, hypertriglyceridemia, increased alanine aminotransferase, 
fatigue, hypercholesterolemia, anemia, and increased aspartate aminotransferase. 
Ridaforolimus exposure at 28 mg/m2 and 33 mg/m2 exceeded adult target levels. 
The RP2D for oral ridaforolimus in children was defined as 33 mg/m2. Four patients 
received at least 4 cycles; 2 with pineoblastoma and diffuse intrinsic pontine glioma 
had stable disease for 12 and 46 cycles, respectively.
Conclusions: Ridaforolimus is orally bioavailable and well tolerated in children 
with advanced solid tumors. The RP2D (33 mg/m2, 5 days/week) exceeds the adult 
RP2D. The favorable toxicity and pharmacokinetic profiles may allow for combination 
therapy, a promising therapeutic option in pediatric malignancies.
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INTRODUCTION
The serine/threonine kinase mTOR is a 
central regulator of cell growth mediated by the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway 
[1-3]. Deregulation of the PI3K/AKT pathway is 
associated with tumorigenesis in a range of human 
cancers, including several pediatric malignancies 
[4-7], and inhibition of this pathway is a promising 
therapeutic strategy. When tested in the US National 
Cancer Institute–supported Pediatric Preclinical Testing 
Program, rapamycin, the prototypic mTOR inhibitor, 
induced significant differences in event-free survival 
distributions compared with controls in 27 of 36 in 
vivo solid tumor models, and objective responses were 
observed in select osteosarcoma, rhabdomyosarcoma, 
and rhabdoid tumor xenografts [8]. Inhibition 
of mTOR decreases VEGF expression in human 
rhabdomyosarcoma cell lines and xenografts, reduces 
tumor angiogenesis in human rhabdomyosarcoma 
xenografts [9, 10], and decreases VEGF expression 
and ezrin-mediated metastatic and invasive behavior 
in murine osteosarcoma cell lines [11, 12], suggesting 
that mTOR inhibition may be promising for treatment 
of sarcomas. Prolonged stable disease was observed 
in a phase 2 study of single-agent therapy with the 
mTOR inhibitor temsirolimus in pediatric patients with 
neuroblastoma and high-grade glioma [13]. Results from 
a Children’s Oncology Group trial in rhabdomyosarcoma 
demonstrated superior event-free survival in patients 
randomized to receive treatment with temsirolimus in 
combination with vinorelbine and cyclophosphamide 
versus treatment with bevacizumab, vinorelbine, and 
cyclophosphamide [14]. This growing body of preclinical 
and clinical evidence has increased interest in mTOR 
inhibitor therapies for pediatric solid tumors.
Ridaforolimus (formerly deforolimus, AP23573, 
or MK-8669) is an orally bioavailable non-prodrug 
analog of rapamycin [15] in clinical development for 
a variety of solid tumors. Studies have shown that 
ridaforolimus selectively and potently inhibits mTOR 
function and proliferative activity in different human 
tumor cell lines in vitro and tumor xenograft models 
in vivo, and has synergistic activity when combined 
with other anticancer agents, such as doxorubicin and 
carboplatin/paclitaxel [16, 17]. In phase 1 and 2 trials, 
ridaforolimus was well tolerated and demonstrated 
clinical activity in adults with advanced solid tumors, 
including those with various sarcomas [18-22]. The 
phase 3 SUCCEED (Sarcoma Multicenter Clinical 
Evaluation of the Efficacy of Ridaforolimus) trial 
reported that oral ridaforolimus reduced the risk of 
progression or death by 28% compared with placebo in 
patients with advanced soft tissue and bone sarcomas 
who had benefited from the immediately preceding 
cytotoxic chemotherapy [23]. Preliminary data suggest 
that ridaforolimus is well tolerated and has clinical 
activity in pediatric patients. In the SUCCEED trial, 
7 pediatric patients aged 13 to 17 years received 
ridaforolimus; 1 had a partial response, 4 had stable 
disease, and 2 had progressive disease [24]. Results 
from a phase 1 study in pediatric patients aged 2 to 16 
years showed that intravenous ridaforolimus (8-16 mg/
m2 daily for 5 consecutive days every other week) was 
well tolerated and associated with stable disease in 6 
(40%) of 15 evaluable pediatric patients with heavily 
pretreated solid tumors, 4 of 6 with central nervous 
system tumors and 2 of 8 with sarcomas [25].
The primary objectives of this phase 1 study 
(NCT01431534) were to define the dose-limiting 
toxicities (DLTs), maximum tolerated dose (MTD), and 
recommended phase 2 dose (RP2D), and to characterize 
the pharmacokinetics of ridaforolimus when orally 
administered to children and adolescents aged 6 to <18 
years with advanced solid tumors. Antitumor activity was 
assessed as a secondary objective. Results from this study 
informed ridaforolimus dose selection for the companion 
phase 1 study (NCT01431547), which investigated 
dalotuzumab monotherapy and ridaforolimus-dalotuzumab 
combination therapy in pediatric patients with advanced 
solid tumors [26].
RESULTS
Patients
Twenty patients were enrolled and treated at 
ridaforolimus dose levels of 22 mg/m2 (n = 4), 28 mg/m2 
(n = 3), and 33 mg/m2 (n = 13). Median age was 13 years 
(range, 8–17 years) and 60% of patients were female 
(Table 1). Tumor diagnoses included: ependymoma in 
4 patients (1 anaplastic and 3 not otherwise specified); 
Ewing sarcoma/peripheral primitive neuroectodermal 
tumor and osteosarcoma in 3 patients each; neuroblastoma 
in 2 patients; and other diagnoses in 8 patients. 
Approximately half of the patients had received at least 
2 prior anticancer regimens (Table 1). Patients received 
between 1 and 46 cycles of study treatment (Figure 1). 
The mean number (± SD) of cycles based on ridaforolimus 
dose levels of 22, 28, and 33 mg/m2 was 4.5 ± 5.0, 2.7 
± 1.2, and 5.7 ± 12.2 cycles, respectively; medians and 
ranges are shown in Table 2. All patients in the 22 mg/
m2 (n = 4) and 28 mg/m2 (n = 3) groups discontinued the 
study due to progressive disease. In the 33 mg/m2 (n = 13) 
group, 10 patients (77%) discontinued due to progressive 
disease, 1 (8%) discontinued due to an adverse event 
(grade 5 gastric perforation related to underlying disease), 
and 2 patients (15%; 1 with pineoblastoma and 1 with 
diffuse intrinsic pontine glioma) entered the extension 
study, in which treatment was continued. Four patients 
received at least 4 courses, 1 with ependymoma (4 cycles 
at 28 mg/m2), 1 with neuroblastoma (7 cycles at 33 mg/
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m2), 1 with pineoblastoma (12 cycles at 22 mg/m2), and 1 
with diffuse intrinsic pontine glioma (46 cycles at 33 mg/
m2 as of January 2016).
Dose-limiting toxicity and RP2D
A total of 18 patients were evaluable for DLTs 
(Table 2). Two patients were not evaluable for DLTs and 
were replaced for the DLT analysis only: 1 patient with 
concomitant administration of a high-dose corticosteroid, 
which could have affected the determination of DLTs, and 
1 patient who had progressive disease before completing 
the DLT assessment period. One DLT of grade 3 increased 
alanine aminotransferase (ALT) occurred in 1 patient at 
the 33 mg/m2 dose. Drug administration was interrupted 
and the DLT resolved. Dose escalation was stopped at 
the highest planned dose level explored in this study, 
33 mg/m2, and the MTD was not determined. Based on 
the toxicity profile, pharmacokinetics, and efficacy (all 
reported below), the RP2D for oral ridaforolimus in 
children was defined as 33 mg/m2, and the expansion 
phase was at this dose.
Adverse events
Nineteen patients (95%) experienced at least 1 
treatment-related adverse event. Table 3  shows treatment-
related adverse events reported in more than 1 patient. 
Treatment-related adverse events reported in ≥30% 
of patients were stomatitis (75%), thrombocytopenia 
(65%), hypertriglyceridemia (50%), increased ALT 
(50%), fatigue (45%), hypercholesterolemia (45%), 
anemia (40%), increased aspartate aminotransferase 
(AST) (40%), leukopenia (35%), nausea (30%), and 
neutropenia (30%).
Treatment-related grade 3/4 adverse events 
were reported in 9 patients (45%). The most common 
treatment-related grade 3/4 adverse events were 
increased ALT (25%) and thrombocytopenia (10%). 
Serious adverse events occurred in 12 patients (60%), 
most of which were disease related. Three patients 
(15%) experienced serious adverse events related to 
study treatment: 1 patient at 22 mg/m2 (grade 3 oral 
herpes) and 2 patients at 33 mg/m2 (grade 2 rectal pain 
in 1 patient and grade 2 seizure in 1 patient). Three 
Table 1: Patient characteristics
Total
N = 20
Ridaforolimus
22 mg/m2
n = 4
Ridaforolimus
28 mg/m2
n = 3
Ridaforolimus
33 mg/m2
n = 13
Median age, years (range) 13.0 (8–17) 13.5 (8–17) 15.0 (12–17) 12.0 (8–17)
Gender, n (%)
 Male 8 (40) 1 (25) 2 (67) 5 (38)
 Female 12 (60) 3 (75) 1 (33) 8 (62)
Tumor diagnosis, n (%)
 Ependymoma (1 anaplastic and 3 NOS) 4 (20) 1 (25) 1 (33) 2 (15)
  Ewing sarcoma/peripheral primitive 
neuroectodermal tumor 3 (15) 1 (25) 0 2 (15)
 Osteosarcoma 3 (15) 1 (25) 1 (33) 1 (8)
 Neuroblastoma 2 (10) 0 0 2 (15)
 Othera 8 (40) 1 (25) 1 (33) 6 (46)
Number of prior therapies, n (%)
 1 8 (40) 2 (50) 1 (33) 5 (38)
 2 3 (15) 0 0 3 (23)
 3 3 (15) 1 (25) 0 2 (15)
 ≥4 4 (20) 1 (25) 2 (67) 1 (8)
 Unknown 2 (10) 0 0 2 (15)
aOther includes 1 patient each with: adrenocortical carcinoma; classical Hodgkin lymphoma; diffuse intrinsic pontine 
glioma; glioblastoma multiforme; pineoblastoma; soft tissue neoplasm, NOS; synovial sarcoma; and Wilms tumor 
(nephroblastoma).
NOS, not otherwise specified.
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deaths occurred during the study, 1 due to neurologic 
symptoms in a patient with central nervous system 
metastases, 1 due to neoplasm progression, and 1 due 
to gastric perforation related to underlying disease. No 
deaths were considered related to ridaforolimus.
Pharmacokinetics
Blood samples for pharmacokinetic evaluation were 
collected from all treated patients, and pharmacokinetic data 
were evaluable for 19 patients. One patient was excluded 
because no dose was administered on day 5. Mean blood 
concentrations of ridaforolimus following oral dosing are 
shown by dose level in Figure 2A, and exposure relative to 
actual dose is plotted in Figure 2B. Trough concentrations 
from predose samples on days 1 through 5 indicated that 
steady-state concentrations had been achieved at day 5. 
Absorption occurred after a lag of approximately 2 hours 
after dosing, and highest blood concentrations were 
generally observed 4 hours after dosing. Concentration-
versus-time profiles were lowest at the 22 mg/m2 dose, 
but nearly superimposable at the 28 mg/m2 and 33 mg/m2 
doses. Exposure at the 28 mg/m2 and 33 mg/m2 dose levels 
(day 5 area under the concentration-versus-time curve 
from 0 to 24 hours [AUC0–24h] = 2,330 and 2,280 h∙ng/
mL, respectively) was approximately 34% higher and 
Figure 1: Time on study. Each bar shows the number of 28-day cycles that a patient received the study treatment, oral ridaforolimus 
(22, 28, or 33 mg/m2) administered once daily for 5 days per week.
Table 2: Dose-escalation and assessment of DLTs in pediatric patients treated with oral ridaforolimus (N = 20)
Dose  
level
Dose,  
mg/m2
Patients 
treated, n
Patients 
evaluable for 
DLT, n
Patients with 
DLT, n
Time to DLT 
onset, days
Median 
(range) time on 
therapy, cycles
1 22 4 3 0 — 2 (2–12)
2 28 3 3 0 — 2 (2–4)
3 33 7 6 1 (grade 3 increased ALT) 22 (cycle 1) 2 (1–46)
a
RP2D 
expansion 33 6 6 0 — —
aCycles on therapy for all patients treated with ridaforolimus 33 mg/m2 during dose escalation and RP2D expansion (n = 13).
Oncotarget84740www.impactjournals.com/oncotarget
Table 3: Treatment-related adverse events overall and in more than 1 pediatric patient treated with ridaforolimus
Total
N = 20
Ridaforolimus
22 mg/m2
n = 4
Ridaforolimus
28 mg/m2
n = 3
Ridaforolimus
33 mg/m2
n = 13
Any
grade
Grades
3–4
Any
grade
Grades
3–4
Any
grade
Grades
3–4
Any
grade
Grades
3–4
Patients with ≥1 treatment-related 
adverse event
19 (95) 9 (45) 3 (75) 2 (50) 3 (100) 2 (67) 13 (100) 5 (38)
Nonhematologic
Stomatitis 15 (75) 0 2 (50) 0 3 (100) 0 10 (77) 0
Fatigue 9 (45) 0 2 (50) 0 1 (33) 0 6 (46) 0
Nausea 6 (30) 0 1 (25) 0 1 (33) 0 4 (31) 0
Dysgeusia 3 (15) 0 0 0 0 0 3 (23) 0
Headache 3 (15) 0 0 0 0 0 3 (23) 0
Photophobia 3 (15) 0 0 0 1 (33) 0 2 (15) 0
Vomiting 3 (15) 0 1 (25) 0 0 0 2 (15) 0
Decreased appetite 2 (10) 0 0 0 0 0 2 (15) 0
Decreased weight 2 (10) 0 0 0 0 0 2 (15) 0
Diarrhea 2 (10) 0 0 0 0 0 2 (15) 0
Dry mouth 2 (10) 0 2 (50) 0 0 0 0 0
Epistaxis 2 (10) 0 0 0 0 0 2 (15) 0
Oral herpes 2 (10) 1 (5) 1 (25) 1 (25) 0 0 1 (8) 0
Rash 2 (10) 0 0 0 1 (33) 0 1 (8) 0
Hematologic
Thrombocytopeniaa 13 (65) 2 (10) 2 (50) 0 1 (33) 1 (33) 10 (77) 1 (8)
Anemiaa 8 (40) 0 2 (50) 0 1 (33) 0 5 (38) 0
Leukopeniab 7 (35) 0 1 (25) 0 2 (67) 0 4 (31) 0
Neutropeniaa 6 (30) 1 (5) 2 (50) 0 0 0 4 (31) 1 (8)
Lymphopeniaa 2 (10) 1 (5) 1 (25) 0 0 0 1 (8) 1 (8)
Biochemical
Hypertriglyceridemiaa 10 (50) 1 (5) 2 (50) 0 1 (33) 0 7 (54) 1 (8)
Increased ALT 10 (50) 5 (25) 1 (25) 1 (25) 1 (33) 1 (33) 8 (62) 3 (23)
Hypercholesterolemiaa 9 (45) 1 (5) 2 (50) 0 1 (33) 1 (33) 6 (46) 0
Increased AST 8 (40) 1 (5) 1 (25) 0 1 (33) 0 6 (46) 1 (8)
Hypophosphatemiaa 5 (25) 1 (5) 2 (50) 1 (25) 1 (33) 0 2 (15) 0
Increased γ-glutamyltransferase 5 (25) 1 (5) 1 (25) 0 1 (33) 0 3 (23) 1 (8)
Hyperglycemiaa 2 (10) 0 0 0 1 (33) 0 1 (8) 0
Hypocalcemiaa 2 (10) 0 1 (25) 0 0 0 1 (8) 0
Hypokalemiaa 2 (10) 0 1 (25) 0 1 (33) 0 0 0
(Continued )
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31% higher, respectively, than target levels based on the 
adult RP2D of 40 mg (once daily for 5 days per week) in 
adults with a mean body surface area (BSA) of 1.8 m2 (day 
5 AUC0–24h = 1,739 h∙ng/mL; data on file with ARIAD 
Pharmaceuticals, Inc./Merck & Co., Inc.). Pharmacokinetic 
parameters are summarized in Table 4. Mean (geometric) 
elimination half-lives were 26 to 27 hours, independent 
of dose level. None of the pharmacokinetic parameters 
appeared to vary with patient age.
Efficacy
None of the patients had a partial or complete 
response. However, 4 patients received at least 4 
courses. One patient with pineoblastoma had stable 
disease for 12 cycles at the 22 mg/m2 dose level before 
disease progression (progression-free survival was 12.8 
months). One patient with diffuse intrinsic pontine 
glioma treated at the 33 mg/m2 dose level continued to 
receive ridaforolimus with stable disease for 46 cycles as 
of January 2016.
DISCUSSION
This is the first trial to evaluate the oral 
formulation of the mTOR inhibitor ridaforolimus in 
pediatric patients. In this phase 1 study, ridaforolimus 
was well tolerated in pediatric patients with advanced 
malignancies, with only 1 DLT (grade 3 increased ALT) 
Figure 2: Pharmacokinetic profile of oral ridaforolimus in pediatric patients. A. Mean (± SD) blood concentration of 
ridaforolimus following oral dosing at 22, 28, and 33 mg/m2 once daily for 5 days per week of a 28-day cycle in pediatric patients. Top 
panel: linear scale; bottom panel: semi-log scale. B. Exposure (AUC0–24h) relative to actual dose of oral ridaforolimus (calculated based on 
body surface area) in pediatric patients.
Total
N = 20
Ridaforolimus
22 mg/m2
n = 4
Ridaforolimus
28 mg/m2
n = 3
Ridaforolimus
33 mg/m2
n = 13
Any
grade
Grades
3–4
Any
grade
Grades
3–4
Any
grade
Grades
3–4
Any
grade
Grades
3–4
Increased alkaline phosphatase 2 (10) 0 1 (25) 0 0 0 1 (8) 0
Increased bilirubin 2 (10) 0 1 (25) 0 0 0 1 (8) 0
Numbers are n (%).
Note: Only the highest reported grade of a given adverse event is counted for an individual patient. Three grade 5 adverse 
events occurred during the study (neurologic symptoms in a patient with central nervous system metastases, neoplasm 
progression, and gastric perforation related to underlying disease); none were related to ridaforolimus, according to the 
investigator. The number of cycles evaluated is shown in Table 2.
aReported as an adverse event by the investigator or based on laboratory values.
bBased on laboratory values only; leukopenia was not reported separately by investigators as a treatment-related adverse event.
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at the highest dose of 33 mg/m2 once daily for 5 days 
per week. Stomatitis and thrombocytopenia were the 
main treatment-related toxicities and were mostly mild 
or moderate in severity. Dose escalation was stopped 
at 33 mg/m2, equivalent to 150% of the adult RP2D 
of 40 mg (assuming an average adult BSA of 1.8 m2) 
[27], and the MTD was not determined. The RP2D for 
oral ridaforolimus in children was defined as 33 mg/
m2, although pharmacokinetic data indicate that 28 mg/
m2 also achieves target concentrations and may also be 
considered for combination treatment.
The toxicity profile for oral ridaforolimus in 
children in this study is comparable to that observed with 
intravenous ridaforolimus in previous studies in adults 
[20, 27] and children [25]. In a phase 1 study in pediatric 
patients with refractory solid tumors, no DLTs were 
observed with intravenous ridaforolimus (8–16 mg/m2 
daily for 5 consecutive days every other week) [25]. The 
most common adverse events in the intravenous pediatric 
study, mostly mild to moderate, were thrombocytopenia, 
anemia, hypertriglyceridemia, leukopenia, elevated AST 
and ALT, and hypophosphatemia [25]. In adults, DLTs 
of grade 2 stomatitis and oral mucositis were observed 
with oral ridaforolimus (the MTD was 40 mg for the 
once daily × 5 days per week regimen) and intravenous 
ridaforolimus (MTD, 18.75 mg/d) [20, 27]. The most 
common treatment-related adverse events in adults were 
grade 1 to 2 mucositis, rash, and anemia with intravenous 
administration [20] and fatigue and mucosal inflammation 
with oral administration [27]. Although the pediatric 
MTD of oral and intravenous ridaforolimus has not been 
identified, evidence of clinical benefit was noted in 2 
(10%) of the 20 treated pediatric patients in our study 
and in 6 (40%) of 15 patients treated with intravenous 
ridaforolimus, 8 to 16 mg/m2 daily for 5 consecutive 
days every other week, in a previous pediatric study 
[25], suggesting that further dose escalation may not be 
necessary.
Although head-to-head trials have yet to be 
conducted, the safety profile of oral ridaforolimus may 
be considered in the context of other mTOR inhibitors 
evaluated in children with refractory solid tumors. In a 
Table 4: Pharmacokinetic parameters for blood concentrations of ridaforolimus on day 5 of oral dosing (once daily × 
5 days per week) according to dose level in pediatric patients
Pharmacokinetic parameter Dose level 1
22 mg/m2
(n = 4)
Dose level 2
28 mg/m2
(n = 3)
Dose level 3
33 mg/m2
(n = 12)a
Day 5 AUC0–24h, h∙ng/mL n = 4 n = 3 n = 11
Geometric mean (CV%b) 1,340 (32) 2,330 (36) 2,280 (30)
C4h, ng/mL n = 4 n = 3 n = 11
Arithmetic mean (SD) 139 (57) 228 (21) 200 (81)
Geometric mean (CV%b) 131 (41) 227 (10) 184 (45)
C8h, ng/mL n = 4 n = 3 n = 12
Arithmetic mean (SD) 74 (23) 119 (35) 118 (39)
Geometric mean (CV%b) 71 (37) 116 (32) 113 (32)
t1/2, h n = 3
c n = 3 n = 9
Arithmetic mean (SD) 25.5 (2.8) 28.2 (9.5) 26.9 (8.7)
Median (range) 24.5 (23.5–28.7) 26.5 (19.7–38.4) 24.9 (21.0–49.1)
Geometric mean (CV%b) 25.5 (10.5) 27.2 (34.5) 26.0 (26.7)
aThirteen patients were enrolled with daily dose administration of ridaforolimus 33 mg/m2; 1 patient was excluded because 
of no exposure on day 5. For 1 patient, AUC, C4h, and t1/2 were not evaluable because of limited sampling. For 2 additional 
patients, t1/2 was not evaluable. The geometric mean of BSADN AUC (n = 11) was 69.8 h∙ng∙m2/(mL∙mg). The lower 
bounds of the 90% 1-sided confidence intervals for the geometric means of day 5 AUC0–24h, C4h, C8h, BSADN AUC, and t1/2 
were 2,020 h∙ng/mL, 154 ng/mL, 100 ng/mL, 61.2 h∙ng∙m2/(mL∙mg), and 23.0 h, respectively. Backtransformed least-
squares mean and confidence interval were performed on natural log-transformed values.
bGeometric coefficient of variation, where CV% = 100 × √(exp [S2] − 1) and S2 is the observed variance on the natural 
logarithmic scale.
cFor 1 patient, t1/2 was not evaluable.
BSADN AUC, area under the concentration-versus-time curve normalized by BSA-adjusted dose; C4h, concentration at 
4 hours; C8h, concentration at 8 hours; CV%, coefficient of variation as a percentage; t1/2, elimination half-life.
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phase 1 trial of temsirolimus administered once weekly to 
children with recurrent or refractory solid tumors, 1 DLT 
(grade 3 anorexia) was observed in 1 of 7 patients who 
received the highest dose tested (150 mg/m2) [28] and 
the phase 2 trial was performed at 75 mg/m2, which, as 
in the ridaforolimus study, was higher than the equivalent 
adult RP2D but was well tolerated [13]. A phase 1 trial of 
oral everolimus in children with refractory solid tumors 
reported DLTs of grade 3 increased ALT (n = 1), grade 
3 mucositis (n = 1), and grade 3 diarrhea (n = 1) in 3 of 
3 patients treated at the highest dose of 6.5 mg/m2 [29], 
and the RP2D of 5 mg/m2 is roughly equivalent to the 
recommended adult dose of 10 mg once daily [29, 30]. 
Ridaforolimus compares favorably in this study, with 1 
DLT reported in 1 patient.
Although limited by the relatively small number 
of sampling time points, the pharmacokinetic profile 
of ridaforolimus in whole blood following oral 
administration to pediatric patients was comparable to 
that observed in previous studies of oral ridaforolimus 
in adult patients [21, 27]. Exposure with the 33 mg/m2 
dose in children was approximately 31% higher than 
with the RP2D in adults (40 mg once daily, 5 days per 
week), suggesting that clinically effective concentrations 
are attained with the 33 mg/m2 dose. The concentration-
versus-time profiles for the 28 mg/m2 and 33 mg/m2 
doses were nearly superimposable, consistent with 
previous reports of a nonlinear relationship between dose 
and ridaforolimus concentration in whole blood [25, 27]. 
The reason the MTD of ridaforolimus was not reached 
may have been because higher doses do not produce 
higher exposures. Rapamycin analogs reach a plateau 
at higher doses due to saturable binding to intracellular 
protein FK506-binding protein in red blood cells [25]. 
The pharmacokinetic plateau observed in whole blood 
may not be observed in serum, because a higher unbound 
fraction is expected at higher concentrations due to 
saturation of FK506-binding protein in the red blood 
cells. This phenomenon supports the use of 33 mg/m2 
rather than 28 mg/m2 as the RP2D. Although the dose 
could potentially be escalated further because the MTD 
was not determined, 33 mg/m2 appears to provide an 
appropriate exposure level in children, given that future 
development of ridaforolimus may involve combination 
therapy to increase efficacy.
Prolonged stable disease was observed in 2 patients 
in this study, 1 patient with pineoblastoma and 1 with 
diffuse intrinsic pontine glioma, with progression-free 
survival of 12.8 months and >42 months, respectively. 
This is consistent with observations that ridaforolimus 
crosses the blood–brain barrier [31] and that the benefit 
of single-agent therapy with an mTOR inhibitor is 
characteristically disease stabilization [25, 28, 29], 
including in patients with diffuse intrinsic pontine 
glioma [13]. While mTOR inhibitors have generally been 
associated with modest clinical activity as single-agent 
therapies, chemotherapy or other targeted agents have 
shown improved effects and even reversed resistance 
when combined with an mTOR inhibitor [14, 32, 33]. 
Preclinical studies of mTOR inhibitors combined with 
insulin-like growth factor 1 receptor (IGF1R) inhibitors 
showed additive or synergistic antitumor activity when 
the agents were combined [34-36], guiding interest in 
combining ridaforolimus with an anti-IGF1R monoclonal 
antibody, dalotuzumab. Two phase 1 studies [34, 37] 
have evaluated ridaforolimus in combination with 
dalotuzumab in adults and have shown that combining 
these agents is feasible and that the combination may 
have synergistic activity in advanced malignancies. 
A positive effect was not observed in a phase 2 study 
of ridaforolimus, dalotuzumab, and exemestane versus 
ridaforolimus and exemestane alone in advanced breast 
cancer [38]; however, lower doses of ridaforolimus 
in the first arm may have contributed to this lack of 
effect. In a phase 1 study of dalotuzumab monotherapy 
and ridaforolimus-dalotuzumab combination therapy 
in pediatric patients (NCT01431547), 1 of 20 patients 
who received dalotuzumab alone achieved a confirmed 
partial response, and none of the 4 patients who received 
the ridaforolimus-dalotuzumab combination achieved 
a response or prolonged stable disease [26]; however, 
it could be valuable to assess the ridaforolimus-
dalotuzumab combination in a larger cohort. 
Ridaforolimus could be combined with other compounds, 
as well.
Validated biomarkers are not currently available 
for the prediction of efficacy and the selection of patients 
for future development of ridaforolimus as an mTOR 
inhibitor in pediatric oncology. Preclinical models and 
early-phase clinical trials have suggested that mutations 
in the PIK3CA gene, PTEN loss of function mutations, and 
high levels of phosphorylated AKT and phosphorylated 
S6 ribosomal protein may predict the efficacy of mTOR 
inhibitors [39, 40]. Future clinical trials should incorporate 
the investigation of biomarkers that may be predictive of 
response to treatment.
In conclusion, ridaforolimus is an investigational, 
orally bioavailable mTOR inhibitor that is well 
tolerated in pediatric patients with advanced solid tumor 
malignancies, with grade 3 increased ALT as a DLT. 
The safety profile observed in children is comparable 
to that observed in adults. The RP2D for ridaforolimus 
in children is 33 mg/m2, 5 days per week, although 
preliminary pharmacokinetic data suggest that 28 mg/
m2 may also be considered. In view of the potency, oral 
bioavailability, and toxicity profile of ridaforolimus in 
the current trial, along with similar pharmacokinetic 
profiles observed with intravenous and oral ridaforolimus 
in previous studies in children and adults, oral 
ridaforolimus may be well suited for combination 
therapy, which may represent an important option for use 
in pediatric malignancies.
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MATERIALS AND METHODS
Patients
Eligible patients were children ≥6 (due to tablet 
size) to <18 years of age at the date of enrollment with 
histologically or cytologically confirmed malignant solid 
tumors, including tumors of the central nervous system 
and lymphoma, that had progressed despite standard 
therapy or for which no effective standard therapy was 
known. Patients who had received standard therapy 
and continued to have biopsy-proven residual stable 
disease were also eligible. In the absence of a biopsy, 
patients with sarcoma were eligible on the basis of 
persistent positron emission tomography activity and 
patients with neuroblastoma were eligible on the basis 
of persistent activity by 123I-metaiodobenzylguanidine 
scan. Diagnoses of diffuse intrinsic pontine glioma 
did not require biopsy. Patients with measurable (per 
Response Evaluation Criteria in Solid Tumors, version 
1.1 [RECIST v1.1]) or nonmeasurable disease were 
eligible. Patients were required to have a BSA within 
the acceptable range for a given dose cohort in order to 
achieve an actual dosing variation of ≤2 mg/m2 above or 
below the target (see dosing nomogram in Supplementary 
Table S1). Other key inclusion criteria were: Lansky 
Play Scale score of ≥70 for children <10 years of age; 
Karnofsky performance score of ≥70 for children aged 
10 to 15 years; Eastern Cooperative Oncology Group 
performance status of 0 to 2 for patients ≥16 years of 
age; absolute neutrophil count of ≥1,000/µL, platelet 
count ≥75,000/µL, serum creatinine level ≤1.5 times 
the upper limit of normal (≤1.5 × ULN) for age, serum 
total bilirubin level ≤1.5 × ULN (or direct bilirubin at 
or below the ULN for patients with total bilirubin >1.5 
× ULN), AST and ALT levels ≤2.5 × ULN (≤5 × ULN 
in patients with liver metastases), fasting serum glucose 
level <160 mg/dL, serum cholesterol level <350 mg/dL, 
and fasting triglyceride level <400 mg/dL. Key exclusion 
criteria were as follows: uncontrolled intercurrent illness; 
poorly controlled type 1 or 2 diabetes (fasting glucose 
level >160 mg/dL); known human immunodeficiency 
virus, hepatitis B virus, or hepatitis C virus infection 
(testing not required); or persistent acute toxicity 
(grade ≥2) from previous therapy, excluding alopecia, 
neuropathy, and hearing loss. Patients who previously 
received rapamycin analogs or were currently receiving 
any other investigational agents were excluded.
The study was conducted in accordance with 
the Declaration of Helsinki, Good Clinical Practice 
guidelines, and all local and federal regulations. The study 
protocol was approved by the Institutional Review Board 
or Ethics Review Committee at each participating site. 
Each patient’s parent or legal guardian provided written 
informed consent, and patients provided assent according 
to local regulations.
Study design and dose escalation
This phase 1, multicenter, open-label study was 
conducted at a total of 8 study sites (3 study sites in the 
United States and 5 Innovative Therapies for Children 
with Cancer [ITCC] Consortium centers [2 in the United 
Kingdom and 3 in France]) between January 31, 2012, 
and the data cutoff, January 14, 2014 (ClinicalTrials.
gov identifier NCT01431534; European Clinical Trials 
Database [EudraCT] number 2011-000729-55). An 
enteric-coated tablet formulation of ridaforolimus was 
orally administered for 5 consecutive days and not 
administered for 2 consecutive days per week in 28-day 
cycles until progression, unacceptable toxicity, or consent 
withdrawal. Patients who did not have disease progression, 
who adequately tolerated therapy, and who continued to 
meet eligibility criteria for 6 months after completion of 
the enrollment period were eligible to enter an extension 
phase of the study. Dose escalation was conducted by 
using a modified toxicity probability intervals method 
[41] that targeted a 30% DLT rate and started at 22 mg/
m2 (the equivalent of the adult RP2D [27], a 40-mg dose 
in adults with a BSA of 1.8 m2). The dose was escalated 
to 28 mg/m2 and 33 mg/m2 (increments of 25% of starting 
dose). Dosing was adjusted based on BSA and rounded 
to the nearest 10-mg tablet. Patients were to be treated at 
sequentially rising dose levels until a preliminary MTD 
was identified.
Safety assessments
Toxicity was graded according to the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events, version 4.0 [42]. Safety data were 
reported for all patients who received at least 1 dose 
of the study drug. A DLT was defined as any of the 
following events considered at least possibly related 
to the study drug and occurring during the first 28-day 
treatment cycle with adequate drug exposure (having 
received >75% of planned doses, exclusive of study drug 
doses missed due to treatment-related toxicity): grade 
3 to 4 neutropenia associated with fever, antibiotics, or 
hospitalization for infection; grade 4 thrombocytopenia 
requiring platelet transfusion; grade 4 neutropenia, grade 
4 thrombocytopenia, or grade ≥3 hyperglycemia persisting 
for ≥5 days; grade ≥3 diarrhea persisting >24 hours; grade 
≥3 nausea, vomiting, or other nonhematologic toxicity 
persisting despite optimal medical management (except 
transient electrolyte abnormalities, transient grade 3 liver 
function test result elevations, grade 3 neurotoxicity in 
patients who had grade 3 neurotoxicity at baseline, and 
hearing loss in patients who had grade 3 hearing loss at 
baseline); or any toxicity considered at least possibly 
related to the study drug that prevents completion of the 
DLT assessment period, or interrupts dosing (or delays 
the next cycle) for >10 dosing days. Once the RP2D of 
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ridaforolimus was defined, an expansion cohort to be 
treated at the RP2D was planned to obtain additional 
safety, tolerability, and pharmacokinetic data.
Pharmacokinetic assessments
Whole blood samples (2 mL each) for 
pharmacokinetic analyses were collected at the following 
time points: <5 minutes before dosing on days 1 through 
5 and at 0.5, 1, 2, 4, 8, 24, and 72 hours after drug 
administration on day 5 of the first week of the first 
treatment cycle. Blood concentrations of ridaforolimus 
were determined using a validated liquid chromatography/
tandem mass spectrometry assay as in previous 
ridaforolimus studies (Charles River Laboratories, 
Shrewsbury, MA) [25, 27]. The pharmacokinetic 
parameters of AUC0–24h and elimination half-life (t1/2) 
were determined by noncompartmental modeling using 
WinNonlin software (Pharsight, Certara, Princeton, NJ).
Efficacy assessments
All patients were to have computed tomography 
or magnetic resonance imaging scans at baseline, every 
2 cycles during treatment, and at the time of treatment 
discontinuation. Local investigator assessment of treatment 
response was performed using RECIST v1.1 [43].
Statistical analyses
Up to approximately 18 patients were to be treated 
during dose escalation depending on empirical safety data, 
with up to approximately 12 patients treated at the MTD (or 
maximum dose if the MTD was not achieved). Assuming 
that the standard deviation of the logarithm of the AUC 
of ridaforolimus is similar to that observed in adults at 
approximately 0.3, with 10 patients the study would have 
approximately 96% power to rule out a 25% drop if the true 
AUC ratio were 1, and approximately 74% power to rule 
out a 25% drop if the true AUC ratio were 0.9, based on a 
type I error rate of 0.1 and a one-sided t test.
At a safe and well-tolerated dose, ridaforolimus was 
considered to have obtained sufficient pharmacokinetic 
properties if the lower bound of the 90% one-sided 
confidence interval for the geometric mean AUC0–24h on day 
5, based on the one-sample t test, exceeded 1,304 h∙ng/mL, 
or 75% of the estimated geometric mean AUC0–24h on day 
5 after a dose of 40 mg in adults (1,739 h∙ng/mL; data on 
file with ARIAD Pharmaceuticals, Inc./Merck & Co., Inc.).
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